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Conclusions: Varenicline 1 mg b.i.d. using a flexible quit date 
paradigm had similar efficacy and safety compared with previous 
fixed quit date studies.
Introduction
Cigarette smoking is the single most important cause of pre-
ventable  morbidity  and  mortality  in  the  developed  world 
(World Health Organization, 2008). The majority of smokers 
express a desire to quit, but annually less than 5%–6% quit and 
maintain abstinence after 1 year (Hughes, Keely, & Naud, 2004). 
Pharmacotherapy can at least double quit rates over counseling 
alone (Fiore et al., 2008; Molyneux et al., 2003) but remains 
underutilized (Shiffman, Brockwell, Pillitteri, & Gitchell, 2008). 
In part, this may be due to medication management guidelines, 
which recommend pharmacotherapy be initiated in relation to 
a fixed quit date (Chambers, 2009; Fiore et al., 2008), with the 
expectation that cessation will occur at treatment initiation or 
shortly thereafter.
Although setting a quit date is thought to increase the prob-
ability of successful quitting (Fiore et al., 2008), we are unaware 
of empirical tests demonstrating the benefit of this approach. 
Gradual cessation studies allow smokers to delay setting a quit 
date until later in the treatment (Hughes, Solomon, Livingston, 
Callas, & Peters, 2010; Shiffman, Ferguson, & Strahs, 2009), but 
we are unaware of abrupt cessation studies that have allowed 
smokers flexible quit dates. The flexibility to quit at some point 
during a period of several weeks after treatment initiation may 
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Introduction:  Current  smoking  cessation  guidelines  recom-
mend setting a quit date prior to starting pharmacotherapy. 
However, providing flexibility in the date of quitting may be 
more acceptable to some smokers. The objective of this study 
was to compare varenicline 1 mg twice daily (b.i.d.) with placebo 
in subjects using a flexible quit date paradigm after starting 
medication.
Methods: In this double-blind, randomized, placebo-controlled 
international study, smokers of ≥10 cigarettes/day, aged 18–75 
years, and who were motivated to quit were randomized (3:1)   
to receive varenicline 1 mg b.i.d. or placebo for 12 weeks. 
Subjects were followed up through Week 24. Subjects were   
instructed to quit between Days 8 and 35 after starting medica-
tion. The primary endpoint was carbon monoxide–confirmed 
continuous abstinence during Weeks 9–12, and a key secondary 
endpoint was continuous abstinence during Weeks 9–24.
Results: Overall, 493 subjects were randomized to varenicline 
and 166 to placebo. Continuous abstinence was higher for var-
enicline  than  for  placebo  subjects  at  the  end  of  treatment 
(Weeks  9–12:  53.1%  vs.  19.3%;  odds  ratio  [OR]  5.9;  95% 
CI, 3.7–9.4; p < .0001) and through 24 weeks follow-up (Weeks 
9–24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6–7.5; p < .0001). 
Serious adverse events occurred in 1.2% varenicline (none were 
psychiatric) and 0.6% placebo subjects. Fewer varenicline than 
placebo  subjects  reported  depression-related  adverse  events 
(2.3% vs. 6.7%, respectively).
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make treatment more acceptable for some smokers. The current 
study  was  designed  to  evaluate  whether  the  most  recently   
approved smoking cessation pharmacotherapy—varenicline—
could be used successfully with a protocol that allowed smokers to 
start medication without fixing the quit date as Day 8 of treatment.
In clinical trials, varenicline increases the odds of quitting 
threefold compared with placebo when used with a fixed quit 
date (Cahill, Stead, & Lancaster, 2008; Gonzales et al., 2006; 
Jorenby et al., 2006). As varenicline is a partial agonist active at 
the  a4b2  nicotinic  acetylcholine  receptor  and  is  believed  to 
block the reward associated with nicotine and reduce nicotine 
craving (Coe et al., 2005), it may be particularly suitable for a 
flexible quit date strategy. After starting varenicline treatment 
while still smoking, smokers find smoking less rewarding (West, 
Baker, Cappelleri, & Bushmakin, 2008). Experiencing the ben-
eficial effects of varenicline while still smoking should increase 
the smoker’s confidence that varenicline will be helpful during a 
quit attempt. Such use also promotes a reduction in cigarettes 
smoked, increases self-efficacy, and decreases nicotine depen-
dence (Hughes et al., 2010). Similarly, “pretreatment” prior to 
the quit date increases abstinence with the nicotine patch (Rose, 
Herskovic, Behm, & Westman, 2009).
Allowing smokers to choose their own quit date within a 
specified  time  period  provides  a  means  for  accommodating 
smokers who are unable or unwilling to set a fixed quit date, 
although we are not aware of any empirical evidence that fixed 
quit dates may be a barrier to treatment uptake. The aim of the 
current study was to examine whether varenicline would be   
effective and have the same safety profile when used within a 
flexible quit date approach to treatment.
Methods
Design Overview
In this randomized, double-blind, placebo-controlled multina-
tional study, smokers interested in quitting were randomized to 
the standard dose of varenicline or placebo. They were free to 
choose to quit at any time between Days 8 and 35 (Weeks 2–5) 
after starting treatment (i.e., following drug titration that took 
place within the first week). The aim was to assess the efficacy 
and safety of 12 weeks of varenicline 1 mg twice daily (b.i.d.) 
versus placebo in aiding cessation within this flexible quit 
date setting and included a 12-week follow-up period without 
medication.
Clinic visits occurred weekly until Week 12 then at Weeks 
13, 16, 20, and 24. Telephone contact was made at Weeks 14, 18, 
and 22. At each visit, subjects were queried about their potential 
quit date, the number of cigarettes smoked per day, and their 
quit attempts since the last visit. A quit attempt was defined as a 
self-reported attempt that lasted for at least a few hours with the 
conviction to quit permanently and included both spontaneous 
and planned attempts. Cessation was monitored by self-report 
and  was  confirmed  by  ≤10  ppm  expired  carbon  monoxide 
(CO).  At  each  clinic  or  telephone  contact,  subjects  received 
brief (up to 10 min) smoking cessation counseling, consistent 
with Agency for Healthcare Research and Quality guidelines 
(Fiore et al., 2008). At baseline, subjects received the Clearing 
the Air: Quit Smoking Today (National Cancer Institute [U.S.], 
2003)  self-help  booklet.  As  in  previous  varenicline  studies, 
subjects were encouraged to continue in the study even if they 
discontinued medication or failed to stop smoking.
To facilitate cross-study comparisons, the same major out-
comes were used as in previous varenicline studies, i.e., contin-
uous abstinence from Weeks 9–12 and Weeks 9–24.
Randomization and Interventions
A  predefined,  central,  computer-generated  randomization   
sequence assigned subjects in a 3:1 ratio to receive either vareni-
cline or placebo (block size: 4, stratified by center). A 3:1 ran-
domization  was  chosen  to  promote  rapid  enrollment   
because the efficacy of varenicline has been established and it is 
commercially available. Varenicline subjects were titrated to the 
full dose during the first week: 0.5 mg once daily for 3 days 
then 0.5 mg b.i.d. for 4 days. Those randomized to placebo   
received matched placebo dosing with identical appearance to 
varenicline.
In order to preserve the blind of the investigative centers, 
subjects,  and  sponsor,  no  unblinded  data  listings  and  tables 
were produced, other than for the Data Monitoring Committee, 
until data from the non-treatment follow-up period had been 
entered into a database and cleaned.
Written informed consent was obtained from all subjects. 
Consent forms and procedures were approved by institutional 
boards at each site. The study was conducted in compliance 
with the ethical principles of the Declaration of Helsinki (World 
Medical Association, 2008) and International Conference on 
Harmonisation Good Clinical Practice guidelines (International 
Conference on Harmonisation of Technical Requirements for 
Registration  of  Pharmaceuticals  for  Human  Use,  1996)  and 
applicable local regulatory requirements and laws. An indepen-
dent  Data  Monitoring  Committee  assured  the  safety  of  the 
subjects.
Setting and Subjects
The  study  was  conducted  at  33  centers  across  14  countries   
(Argentina,  Brazil,  Canada,  China,  Czech  Republic,  France, 
Germany, Hungary, Italy, Mexico, Republic of Korea, Taiwan, 
United Kingdom, and United States), between September 22, 
2008 and December 10, 2009. Sites included research centers, 
private practice offices, and research clinics. Many centers in 
multiple countries were used in order to increase the external 
validity of the trial and to facilitate expeditious recruitment.   
Enrollment per center varied from 9 (1.4%) to 43 (6.5%) sub-
jects with 17 centers enrolling between 16 and 20 subjects.
Inclusion and exclusion criteria were similar to the vareni-
cline registration studies (Gonzales et al., 2006; Jorenby et al., 
2006).  Male  and  female  smokers  were  eligible  for  the  study 
if  they  were  aged  between  18  and  75  years,  had  smoked   
≥10 cigarettes/day during the previous year with no longer than 
3 months abstinence during that time, and were motivated to 
stop smoking.
Subjects  were  excluded  from  the  study  if  they  had  used   
a  nicotine  replacement  product,  bupropion,  clonidine,  or   
nortriptyline within the past 3 months or had taken varenicline 
previously. Subjects were also excluded for serious or unstable 345
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psychiatric disorders in the past 6 months or on the basis of 
medical  history.  This  encompassed  current  depression  or   
depression diagnosed or treated within the past 12 months; any 
history  of  suicidal  ideation  or  suicidal  behavior  in  the  past   
5 years; past history of—or present—psychosis, panic attacks, or 
anxiety disorders; or bipolar disorder. It also excluded those with 
a history of drug (except nicotine) or alcohol abuse/dependence 
within the past 12 months and those with a positive urine drug 
screen for drugs of abuse/potential abuse not prescribed for the 
treatment of a medical condition.
Outcomes and Follow-up
The  primary  efficacy  objective  was  to  compare  12  weeks  of   
varenicline 1 mg b.i.d. with placebo for smoking cessation in the 
setting of subject self-selected quit date. The primary efficacy 
endpoint was 4-week continuous abstinence for Weeks 9–12. 
The key secondary efficacy endpoint was continuous abstinence 
from Weeks 9 to 24. Additional secondary endpoints included 
the 7-day point prevalence of abstinence at Weeks 12 and 24 
and time to first quit attempt.
Adverse  events  were  recorded  and  subsequently  system-
atized  using  the  Medical  Dictionary  for  Regulatory  Activities 
(MedDRA). Additionally, at each contact, two neuropsychiatric 
assessments were conducted: interviewer–administration of the 
Columbia  Suicide-Severity  Rating  Scale  (C-SSRS;  Posner, 
Oquendo, Gould, Stanley, & Davies, 2007) to assess suicidal 
ideation and behavior and self-administration of the Patient 
Health Questionnaire (PHQ-9; Kroenke, Spitzer, & Williams, 
2001) to assess depression/depressed mood.
Statistical Analyses
Logistic regression models were used to assess primary and key 
secondary endpoints. The model included treatment and center 
as independent variables. The type 1 family-wise error rate of 
.05, for the analyses of the primary and key secondary endpoints, 
was  preserved  using  a  step-down  procedure.  The  hierarchy  of 
comparisons was (1) 4-week continuous abstinence for Weeks 
9–12 and (2) continuous abstinence for Weeks 9–24. For these 
endpoints, expanded logistic regression models were used to   
assess the center by treatment interaction. The primary efficacy 
analysis population was all subjects randomized to treatment. 
Subjects who discontinued the study were assumed to be smokers 
from the point of discontinuation to end of study. In the case of 
missed  visits  during  the  evaluation  periods  for  continuous   
abstinence (Weeks 9–12 and 9–24), a subject was considered 
abstinent if they reported they had not smoked or used nicotine 
products “since the last visit” at the first visit after the missing 
visit(s).  Missing  CO  measurements  did  not  disqualify  the 
subject for abstinence endpoints. All statistical testing was 
two sided and used a .05 level of significance (no adjustment 
for multiplicity was used other than for the primary and key 
secondary endpoints).
The Kaplan–Meier method was used to analyze the time to 
first quit attempt, defined as the number of days from the first 
dose of study medication to the date of the first quit attempt 
based on subjects who took at least one dose of study medica-
tion. Subjects who did not report quit attempts within the quit 
window, or who had missing data, were classified as censored, 
and their time to first quit attempt was set to Day 35.
Expanded logistic regression models were used to assess 
the  impact  of  country  and  baseline  characteristics  on  the   
primary and key secondary outcomes. The sample size calcula-
tion was based on a two-group continuity-corrected Pearson 
chi-square two-sided test with a .05 significance level and a 3:1 
randomization ratio of varenicline to placebo. Assuming true 
continuous abstinence rates of 0.24 for Weeks 9–12 and 0.18 
for Weeks 9–24 for placebo and continuous abstinence rates of 
0.46 for Weeks 9–12 and 0.31 for Weeks 9–24 for varenicline, 
a sample size of 652 subjects was calculated. This provided at 
least 90% power to detect a difference between the varenicline 




Of 831 screened subjects, 172 did not fulfill the inclusion criteria, 
the most frequent reason being a positive urine drug test result 
(26.7%). In total, 493 subjects were randomized to varenicline 
and 166 to placebo and were included in the efficacy analysis. Of 
these, 486 in the varenicline group and 165 in the placebo group 
received at least one dose of medication and were included in 
the safety analysis. There were 61 (12.4%) subjects who discon-
tinued treatment in the varenicline arm (24 [4.9%] due to ad-
verse events [AEs]) and 34 (20.5%) in the placebo arm (13 
[7.8%] due to AEs). Some of the subjects who discontinued 
treatment remained in the study. Overall, 425 (86.2%) subjects 
completed the 24 weeks of the study in the varenicline arm and 
141 (84.9%) in placebo. The flow of subjects through the study 
is shown in full in Supplementary Figure 1.
The  two  treatment  groups  were  similar  with  respect  to   
baseline demographics, smoking history, and level of nicotine 
dependence (Table 1).
Study completion rates were similar for both study groups: 
86.2% (n = 425) for varenicline and 84.9% (n = 141) for placebo. 
The median duration of treatment (study drug exposure) was 
83 days for each of the treatment groups, and the majority of 
subjects were exposed for 61–90 days across the two treatment 
groups.
Efficacy Outcomes
Among  all  randomized  subjects,  CO-confirmed  continuous   
abstinence  was  significantly  higher  for  those  randomized  to   
varenicline than for those randomized to placebo at the end of 
treatment (Weeks 9–12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 
95% CI, 3.7–9.4; p < .0001; Figure 1) and at Week 24 (Weeks 
9–24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6–7.5; p < .0001). For 
both  endpoints,  the  result  of  the  expanded  models  showed   
no  statistically  significant  interaction  (p  >  .5)  of  center  and 
treatment.
Seven-day point prevalence of abstinence rates were signifi-
cantly higher for varenicline compared with placebo at the end 
of treatment at Week 12 (varenicline 58.6% vs. placebo 24.1%; 
OR 5.6; 95% CI, 3.6–8.6; p < .0001) and at the end of follow-up 
at Week 24 (varenicline 42.4% vs. placebo 17.5%; OR 4.1; 95% 
CI, 2.6–6.5; p < .0001). Seven-day point prevalence of absti-
nence rates is shown in Supplementary Figure 2.346
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Moderators of Study Results
The results of the models exploring the effect of replacing inves-
tigative centers by country showed a significant effect on con-
tinuous abstinence at Weeks 9–12 (p < .0001) but no significant 
interaction  with  the  treatment  (p  >  .4).  A  series  of  models 
adjusting separately for gender, age, race, Fagerström Test for 
Nicotine Dependence score, and average number of cigarettes 
per day over the last month showed that adjusted ORs for vare-
nicline versus placebo ranged from 5.92 to 6.42, favoring active 
medication. None of the treatment by baseline characteristic   
interactions was significant (all p > .1226), i.e., the efficacy of 
varenicline was stable across variations in baseline characteristics.
Time to First Quit Attempt
By the end of the quit window (Day 35), 391 (80.5%) varenicline 
subjects and 121 (73.3%) placebo subjects reported making a 
quit attempt (p = .062). Varenicline-treated subjects made their 
first quit attempt significantly earlier than placebo-treated 
subjects (p = .0074), with a median of 17 versus 24 days, respec-
tively (Figure 2).
Safety Outcomes
Varenicline was generally well tolerated and had a safety profile 
similar to previous clinical trials (Gonzales et al., 2006; Jorenby 
et al., 2006). The most frequent adverse events (occurring in 
≥5% of either treatment group) were nausea, headache, insomnia, 
nasopharyngitis,  and  abnormal  dreams  (Table  2).  Serious 
adverse  events  occurred  in  six  (1.2%)  varenicline  subjects   
(intervertebral disc protrusion [two cases], carotid artery stenosis, 
syncope,  peripheral  arterial  occlusive  disease,  and  ureteric   
calculus with obstruction) and one (0.6%) placebo subject 
(suicidal ideation).
Other than sleep disorders, psychiatric adverse events were 
uncommon (<5%) in both groups (Table 2). Depressed mood 
was experienced by 1% and 3% and depression by 0.8% and 3% 
of varenicline and placebo subjects, respectively. A similar number 
of subjects had an increase in the PHQ-9 depression severity 
categorization in both varenicline (13.4%) and placebo (17.6%) 
treatment groups. Most often, these shifts were from “None” at 
screening and baseline to a postbaseline assessment of “Mild.” 
One varenicline subject (0.2%) and two (1.2%) placebo subjects 
had positive postbaseline C-SSRS answers for suicidal ideation 
and reported these adverse events during the study. There were 
no instances of suicide attempts.
Discussion
In  this  randomized  placebo-controlled  trial,  varenicline  was 
found to be efficacious for smoking cessation in a flexible quit 
date setting. For continuous abstinence at the end of treatment, 
the OR of 5.9 in favor of varenicline is toward the mid-to-upper 
end of ORs observed in previously published smoking cessation 
randomized,  placebo-controlled  clinical  trials  of  varenicline 
with a similar dose regimen and treatment duration (OR range: 
2.3–8.4; Gonzales et al., 2006; Jorenby et al., 2006; Nakamura 
et al., 2007; Oncken et al., 2006; Rigotti et al., 2010; Tashkin 
et al., 2010; Tsai et al., 2007; Wang et al., 2009). The difference 
was maintained through 24 weeks, with the OR of 4.4 being 
Table 1. Subject Baseline Characteristics
Varenicline (n = 493) Placebo (n = 166)
Overall subjects per site, median (range) 20 (9–43)
Demographic characteristics
  Age, years, mean (SD) 43.9 (12.5) 43.2 (12.2)
  Men, n (%) 296 (60.0) 99 (59.6)
  Race, n (%)
    White 335 (68.0) 113 (68.1)
    Black 33 (6.7) 8 (4.8)
    Asian 103 (20.9) 36 (21.7)
    Other 22 (4.5) 9 (5.4)
  Body mass index, kg/m2, mean (SD) 26.2 (4.3) 26.7 (4.7)
Smoking history
  Years smoked cigarettes, mean (range) 26.0 (2–57) 24.6 (2–59)
  Cigarettes/day (past month), mean (range) 21.3 (10–70) 21.5 (10–65)
  ≥1 previous quit attempt, n (%) 334 (67.7) 106 (63.9)
  Longest previous abstinent period in past year, days, mean (range) 4.4 (0–90) 4.7 (0–90)
  Fagerström Test for Nicotine Dependence Score, mean (SD)a 5.6 (2.2) 5.4 (2.1)
Note. aScores range from 0 to 10, with higher scores indicating greater dependence.
Figure 1.  Continuous abstinence at Weeks 9–12 and 9–24. OR = odds 
ratio (shown with 95% CI).347
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close to the upper value of the range for ORs of previously pub-
lished clinical trials of varenicline (OR range: 1.9–4.9; Gonzales 
et al., 2006; Jorenby et al., 2006; Nakamura et al., 2007; Oncken 
et al., 2006; Rigotti et al., 2010; Tashkin et al., 2010; Tsai et al., 
2007; Wang et al., 2009). Continuous abstinence for varenicline 
of 53.1% for Weeks 9–12 is in the mid range of continuous   
abstinence observed in previous studies of varenicline (range: 
42.3%–65.4%), as is the continuous abstinence of 34.7% for 
Weeks 9–24 (range: 25.8%–46.8%; Gonzales et al., 2006; Jorenby 
et  al.,  2006;  Nakamura  et  al.,  2007;  Oncken  et  al.,  2006; 
Rigotti et al., 2010; Tashkin et al., 2010; Tsai et al., 2007; Wang 
et al., 2009).
One  potential  drawback  of  allowing  smokers  to  delay   
setting a quit date until after starting pharmacotherapy might be 
an  increased  probability  of  the  smoker  postponing  the  quit   
attempt indefinitely. However, in this study, 80.6% of varenicline 
and 73.3% of placebo subjects reported making a quit attempt 
during the quitting window. The number of subjects who made 
a quit attempt during the treatment phase is actually higher   
because there are some subjects (44 [9.1%] receiving varenicline 
and  7  [4.2%]  receiving  placebo)  who  were  abstinent  during 
Weeks 9–12 but did not report an attempt in the quit window. 
These subjects either made their first quit attempt outside the 
quit window (during Weeks 6–9) or failed to report it during 
the quit window. Thus, the vast majority of subjects made a quit 
attempt during the first 9 weeks of the study. The median time 
to quit attempt in the varenicline group in this flexible protocol 
was longer than in the traditional fixed quit date protocol (17 vs. 
8 days), assuming that everybody in the previous studies made a 
quit attempt on Day 8, as required by the protocol. However, 
this extended time to quit date did not appear to result in lower 
efficacy than that observed in previous studies with a similar 
population (Gonzales et al., 2006; Jorenby et al., 2006).
Prolongation  of  the  precessation  treatment  period  may   
have allowed smokers to experience the reward-blocking and 
craving-relieving benefits of varenicline prior to the quit date 
and thus increased their confidence and motivation to make   
a  quit  attempt  and  remain  abstinent  after  the  quit  attempt.   
Although we observed improved abstinence with varenicline   
in this study, relative to placebo, we did not observe more quit 
attempts in the active drug group. This is probably due to the 
fact that smokers entering a clinical trial are typically highly   
motivated to quit smoking; therefore, the vast majority of sub-
jects in both treatment arms made at least one attempt. In addi-
tion, unlike in prior studies (Gonzales et al., 2006; Jorenby et al., 
2006), the time between the target quit date and follow-up var-
ied  among  individuals,  resulting  in  an  increase  in  the  days 
smokers in the varenicline group were at risk for relapse, since 
on average they quit earlier than the placebo group. However, 
this did not unfavorably influence the abstinence rates in the 
active treatment group.
The overall safety profile observed in this trial was similar to 
previous  community  trials  with  varenicline  (Gonzales  et  al., 
2006; Jorenby et al., 2006). Gastrointestinal and sleep-related 
adverse events were higher in the varenicline group compared 
with placebo, but few subjects discontinued treatment due to 
adverse events. In fact more placebo than varenicline subjects 
discontinued due to adverse events (7.9% vs. 4.9%, respectively). 
Psychiatric adverse events appeared to be less prevalent in the 
varenicline than in the placebo group. Exclusion of subjects 
with psychiatric illness was a limitation of this study.
As discussed above, the odds of quitting with this protocol 
were within the range observed in studies in which subjects were 
required to set a quit date a priori, which possibly suggests no 
particular disadvantage to using a fixed quit date approach in 
terms of overall treatment efficacy. However, such cross-study 
comparisons can be misleading; thus only a randomized trial 
would answer whether a fixed quit date or a flexible quit date 
protocol is superior. The present study was not designed to   
determine  which  cessation  paradigm  would  be  superior.  By 
Figure 2.  Time to first quit attempt (Kaplan–Meier).348
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demonstrating similar effect size, however, the current study 
demonstrates that a flexible quit strategy is an effective option 
and that a study comparing flexible with fixed quit dates in a 
general population would need to be very large. Alternatively, if 
the two approaches to quitting are more suitable for different 
smoker populations, a direct comparison may not be relevant. 
Our results are consistent with two prior studies examining the 
effect of precessation nicotine replacement therapy in conjunction 
with a flexible quit date (Hughes et al., 2010; Shiffman et al., 
2009); however, these studies used a gradual cessation approach 
and were conducted among smokers who were less motivated   
to quit.
Allowing smokers to start treatment without setting a fixed 
quit date may make quitting more appealing to some smokers. 
Current  guidelines  recommend  that  all  smokers  should  be 
counseled at every clinical encounter to quit (Fiore et al., 2008). 
Those willing to make a quit attempt should be supported to the 
fullest extent possible. For the clinician with a smoker willing to 
quit but unable to commit to a fixed quit date, the current study 
endorses an alternative approach: quitting within a flexible quit 
window.
Supplementary Material
Supplementary  Figures  1  and  2  can  be  found  online  at   
http://www.ntr.oxfordjournals.org
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Table 2. Adverse Events, Shown As n (%)
Varenicline (n = 486) Placebo (n = 165)
Any adverse events 348 (71.6) 89 (53.9)
Severe adverse events 43 (8.8) 18 (10.9)
Serious adverse events 6 (1.2) 1 (0.6)
Deaths (all causes) 0 0
Study drug discontinuations due to adverse events
  All causes 24 (4.9) 13 (7.9)
  Nausea 5 (1.0) 0
  Dose reductions or temporary discontinuations due to adverse events 53 (10.9) 5 (3.0)
Most frequent adverse events (≥5% in either group; except psychiatric adverse events)
  GI disorders
    Nausea 142 (29.2) 15 (9.1)
  Infections and infestations
    Nasopharyngitis 34 (7.0) 14 (8.5)
  Nervous system disorders
    Headache 55 (11.3) 20 (12.1)
Psychiatric adverse events (≥1% in any group)
  Anxiety disorders and symptoms 13 (2.7) 8 (4.8)
  Anxiety 4 (0.8) 5 (3.0)
Depressed mood disorders and disturbances 11 (2.3) 11 (6.7)
  Depressed mood 5 (1.0) 5 (3.0)
  Depression 4 (0.8) 5 (3.0)
  Mood disorders and disturbances (not elsewhere) classified 8 (1.6) 2 (1.2)
  Psychiatric disorders (not elsewhere classified) 2 (0.4) 2 (1.2)
Sleep disorders and disturbances 116 (23.9) 17 (10.3)
  Abnormal dreams 61 (12.6) 5 (3.0)
  Insomnia 43 (8.8) 6 (3.6)
  Nightmare 8 (1.6) 2 (1.2)
Sleep disorder 20 (4.1) 6 (3.6)
Suicidal and self-injurious behaviors 1 (0.2) 2 (1.2)
  Suicidal ideation 1 (0.2) 2 (1.2)
Note. Adverse events were defined as those that began or increased in severity during study drug treatment or up to 30 days after the last dose, 
irrespective of the causal relationship to study drug according to the investigator’s opinion.349
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consultancy (EK); and development of educational materials (EK 
and  TR).  CA,  LSA,  and  CR  are  employees  of  Pfizer  Inc.  JH   
has received consulting fees from several non-profit and for-profit 
entities that develop or promote smoking cessation products or that 
advocate for tobacco control measures.
Acknowledgments
Editorial assistance in the form of proofreading, collation of   
review comments, formatting the manuscript for submission, 
preparation  of  figures,  and  formatting  of  references  was   
provided by Tina Morley and Abegale Templar, PhD, of UBC 
Scientific Solutions and was funded by Pfizer Inc. The authors 
would like to thank all study site personnel involved in the 
study.  The  Principle  Investigators  were:  Argentina:  Marta 
Angueira  (Instituto  Medico  Especializado);  Brazil:  Elie  Fiss 
(Fundação do ABC e Faculdade de Medicina do ABC); Canada: 
Claude Gagne (Lipid Research Center); Douglas S. Helmersen 
(Peter  Lougheed  Center);  China:  Ping  Chen  (The  General   
Hospital of Shenyang Military Command); Rong Chang Chen 
(Guangzhou  Institute  of  Respiratory  Disease);  Chen  Wang 
(Beijing Chaoyang Hospital); Czech Republic: Ondrej Sochor 
(Fakultni nemocnice u sv. Anny v Brne); France: Beatrice Le 
Maitre (CHU Côte de Nacre, Unité de Coordination de Taba-
cologie); Germany: Isabelle Schenkenberger (Klinische Forschung 
Berlin); Hungary: Iren Herjavecz (Orszagos Koranyi TBC es 
Pulmonologiai  Intezet);  Maria  Szilasi  (Debreceni  Egyetem 
Orvos—es Egeszsegtudomanyi Centrum); Italy: Laura Carrozzi 
(Dipartimento Cardiotoracico—Azienda Ospedaliero Univer-
sitaria Pisana); Mexico: Rodolfo Posadas (Hospital Universita-
rio Dr. Jose E. Gonzalez); Republic of Korea: Ho Joong Kim 
(Samsung Medical Center); Young Whan Kim (Division of 
Pulmonary and Critical Care Medicine); Taiwan: Huey-Shinn 
Cheng  (Chang  Gung  Memorial  Hospital-Linkou);  Kuang-
Chieh Hsueh (Kaohsiung Veterans General Hospital); United 
Kingdom: Alex Bobak (Wandsworth Medical Centre); United 
States: Corey G. Anderson (Dedicated Clinical Research, Inc.); 
James  L.  Borders  (Central  Kentucky  Research  Association, 
Inc.); Victor Alan Elinoff (Regional Clinical Research, Inc.); 
Gary E. Johnson (Paramount Clinical Research); Nabil Charle 
Morcos  (Apex  Research  Institute);  Anthony  D.  Puopolo   
(Milford  Emergency  Associates,  Inc.);  Jon  Andrew  Shapiro 
(Philadelphia Health Associates—Adult Medicine); Stephan 
C. Sharp (Clinical Research Associates, Inc.); Mark Edward 
Shirley (Omaha Clinical Research, P.C.); Donald P. Tashkin 
(UCLA Medical Center); Bradley D. Vince (Vince and Associ-
ates Clinical Research).
References
Cahill, K., Stead, L. F., & Lancaster, T. (2008). Nicotine receptor par-
tial agonists for smoking cessation. Cochrane Database of Systemic 
Reviews, (3), CD006103. doi:10.1002/14651858.CD006103.pub3
Chambers, M. (2009). NHS stop smoking services: Service and 
monitoring guidance 2010/11. Retrieved. from http://www.scsrn.
org/policy_guidance/2010_11_NHS_Stop_Smoking_Services_
service_and_monitoring_guidance.pdf.
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, 
E. P., Huang, J., et al. (2005). Varenicline: An a4b2 nicotinic 
receptor  partial  agonist  for  smoking  cessation.  Journal  of 
Medicinal Chemistry, 48, 3474–3477. doi:10.1021/jm050069n
Fiore, M. C., Jaén, C. R., Baker, T. B., Bailey, W. C., Benowitz, 
N. L., Curry, S. J., et al. (2008). Treating tobacco use and depen-
dence: 2008 update. Clinical practice guideline. Retrieved from 
http://www.surgeongeneral.gov/tobacco/treating_tobacco_
use08.pdf.
Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., 
Billing, C. B., et al. (2006). Varenicline, an a4b2 nicotinic ace-
tylcholine receptor partial agonist, vs sustained-release bupro-
pion  and  placebo  for  smoking  cessation:  A  randomized 
controlled  trial. Journal  of  the  American  Medical  Association, 
296, 47–55. doi:10.1001/jama.296.1.47
Hughes, J. R., Keely, J., & Naud, S. (2004). Shape of the relapse 
curve  and  long-term  abstinence  among  untreated  smokers.   
Addiction, 99, 29–38. doi:10.1111/j.1360-0443.2004.00540.x
Hughes, J. R., Solomon, L. J., Livingston, A. E., Callas, P. W., & 
Peters, E. N. (2010). A randomized, controlled trial of NRT-
aided gradual vs. abrupt cessation in smokers actively trying to 
quit. Drug and Alcohol Dependence, 111, 105–113. doi:10.1016/
j.drugalcdep.2010.04.007
International  Conference  on  Harmonisation  of  Technical   
Requirements for Registration of Pharmaceuticals for Human 
Use. (1996). ICH harmonised tripartite guideline: Guideline for 
good  clinical  practice  E6(R1).  Retrieved  from  http://www.ich.
org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/ 
Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.
Jorenby, D. E., Hays, J. T., Rigotti, N. A., Azoulay, S., Watsky, E. J., 
Williams, K. E., et al. (2006). Efficacy of varenicline, an a4b2 
nicotinic acetylcholine receptor partial agonist, vs placebo or 
sustained-release bupropion for smoking cessation: A randomized 
controlled  trial. Journal  of  the  American  Medical  Association, 
296, 56–63. doi:10.1001/jama.296.1.56
Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: 
Validity  of  a  brief  depression  severity  measure.  Journal  of 
General  Internal  Medicine,  16,  606–613.  doi:10.1046/j.1525-
1497.2001.016009606.x
Molyneux, A., Lewis, S., Leivers, U., Anderton, A., Antoniak, M., 
Brackenridge, A., et al. (2003). Clinical trial comparing nicotine 
replacement therapy (NRT) plus brief counselling, brief coun-
selling alone, and minimal intervention on smoking cessation   
in  hospital  inpatients.  Thorax,  58,  484–488.  doi:10.1136/
thorax.58.6.484
Nakamura,  M.,  Oshima,  A.,  Fujimoto,  Y.,  Maruyama,  N.,   
Ishibashi, T., & Reeves, K. R. (2007). Efficacy and tolerability of 
varenicline,  an  a4b2  nicotinic  acetylcholine  receptor  partial 
agonist, in a 12-week, randomized, placebo-controlled, dose-
response study with 40-week follow-up for smoking cessation in 
Japanese  smokers.  Clinical  Therapeutics,  29,  1040–1056. 
doi:10.1016/j.clinthera.2007.06.012
National Cancer Institute (U.S.). (2003). Clearing the air: Quit 
smoking  today.  NIH  publication  03-1647.  Retrieved  from 
http://scc.uchicago.edu/pdf/library/stop_smoking_nci.pdf.350
Efficacy of varenicline with flexible quit date
Oncken, C., Gonzales, D., Nides, M., Rennard, S., Watsky, E., 
Billing, C. B., et al. (2006). Efficacy and safety of the novel selec-
tive nicotinic acetylcholine receptor partial agonist, varenicline, 
for smoking cessation. Archives of Internal Medicine, 166, 1571–
1577. doi:10.1001/archinte.166.15.1571
Posner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. 
(2007). Columbia Classification Algorithm of Suicide Assessment 
(C-CASA): Classification of suicidal events in the FDA’s pediatric 
suicidal  risk  analysis  of  antidepressants.  American  Journal  of 
Psychiatry, 164, 1035–1043. doi:10.1176/appi.ajp.164.7.1035
Rigotti,  N.  A.,  Pipe,  A.  L.,  Benowitz,  N.  L.,  Arteaga,  C.,   
Garza, D., & Tonstad, S. (2010). Efficacy and safety of vareni-
cline for smoking cessation in patients with cardiovascular dis-
ease: A randomized trial. Circulation, 121, 221–229. doi:10.1161/
CIRCULATIONAHA.109.869008
Rose, J. E., Herskovic, J. E., Behm, F. M., & Westman, E. C. (2009). 
Precessation treatment with nicotine patch significantly increases 
abstinence rates relative to conventional treatment. Nicotine & 
Tobacco Research, 11, 1067–1075. doi:10.1093/ntr/ntp103
Shiffman, S., Brockwell, S. E., Pillitteri, J. L., & Gitchell, J. G. 
(2008).  Use  of  smoking-cessation  treatments  in  the  United 
States. American Journal of Preventive Medicine, 34, 102–111. 
doi:10.1016/j.amepre.2007.09.033
Shiffman, S., Ferguson, S. G., & Strahs, K. R. (2009). Quitting by 
gradual smoking reduction using nicotine gum: A randomized 
controlled trial. American Journal of Preventive Medicine, 36, 
96–104. doi:10.1016/j.amepre.2008.09.039
Tashkin, D. P., Rennard, S., Hays, J. T., Ma, W., Lawrence, D., & 
Lee, T. C. (2010). Effects of varenicline on smoking cessation in 
mild-to-moderate COPD: A randomized controlled trial. Chest. 
139: 591–599. doi:10.1378/chest.10-0865
Tsai, S. T., Cho, H. J., Cheng, H. S., Kim, C. H., Hsueh, K. C., 
Billing,  C.  B.,  Jr.,  et  al.  (2007).  A  randomized,  placebo- 
controlled trial of varenicline, a selective a4b2 nicotinic acetyl-
choline receptor partial agonist, as a new therapy for smoking 
cessation  in  Asian  smokers.  Clinical  Therapeutics,  29,  1027–
1039. doi:10.1016/j.clinthera.2007.06.011
Wang, C., Xiao, D., Chan, K. P., Pothirat, C., Garza, D., &   
Davies, S. (2009). Varenicline for smoking cessation: A placebo-
controlled,  randomized  study.  Respirology,  14,  384–392. 
doi:10.1111/j.1440-1843.2008.01476.x
West, R., Baker, C. L., Cappelleri, J. C., & Bushmakin, A. G. 
(2008).  Effect  of  varenicline  and  bupropion  SR  on  craving,   
nicotine withdrawal symptoms, and rewarding effects of smoking 
during  a  quit  attempt.  Psychopharmacology,  197,  371–377. 
doi:10.1007/s00213-007-1041-3
World Health Organization. (2008). WHO report on the global 
tobacco epidemic, 2008. The MPower package. Retrieved from 
http://www.who.int/tobacco/mpower/gtcr_download/en/ 
index.html.
World Medical Association. (2008). World Medical Association 
Declaration of Helsinki—ethical principles for medical research 
involving human subjects. Retrieved from http://www.wma.net/
en/30publications/10policies/b3/index.html.